SecBot SecBot
8-K ·Filed Nov 5, 2026

GH

Guardant Health, Inc.
BULLISH
Impact 6/10
Horizonweeks Processed11d 10h ago SEC0001576280-26-000043
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The revenue beat and raised guidance confirm strong commercial momentum, especially in Shield screening. The GAAP EPS miss is secondary given the non-cash stock-based compensation. Watch for Shield volume trajectory toward 285K-290K tests and further margin expansion from the new lower-COGS workflow.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$150.87
T+0 close · Nov 5, 2026 · via day close
Latest settled
+0.55%
T+5 · $151.70
Vs SPY
−2.04%
α at T+5
Next horizon
T+20
in 20d
  1. T+0 · Nov 6 $150.87entry
  2. T+1 · 8d ago +5.25%α +2.88% · $158.79
  3. T+5 · 4d ago +0.55%α −2.04% · $151.70
  4. T+6 · todayOpen
  5. T+20 · in 20d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Guardant Health reported Q3 2026 revenue of $361.0M, up 36% YoY and above the $350.6M consensus, while GAAP net loss per share was -$0.93, wider than the -$0.31 consensus estimate. The company raised full-year 2026 revenue guidance to $1.36-$1.37B (from $1.34-$1.36B), driven by strong Screening (Shield) and Oncology volume growth. The EPS miss reflects elevated operating expenses and stock-based compensation, but the revenue beat and guidance raise support the bullish case.

Key Financial Metrics

EPS
−$0.93
est −$0.31 · -200.0%
Revenue
$361.0M
est $350.6M · +3.0% · +36.1% YoY
Rating
in line
Guidance
$1.36B-$1.37B
raised
Free Cash Flow
-$37.2M
Gross Margin
65.4%

Key Facts

  • Q3 2026 total revenue $361.0M, +36% YoY from $265.2M
  • GAAP net loss per share -$0.93 vs consensus -$0.31
  • Non-GAAP net loss per share -$0.29 vs -$0.39 YoY
  • Oncology revenue $231.3M (+25% YoY), 117,000 tests (+58%)
  • Screening revenue $67.6M (+180% YoY), 83,000 Shield tests (+246%)
  • Biopharma Data revenue $59.0M (+8% YoY)
  • Non-GAAP gross margin 67%, up from 66% YoY
  • Full-year 2026 revenue guidance raised to $1.36-$1.37B (38%-40% growth)
  • Screening revenue guidance raised to $233-$238M, Shield volume 285K-290K tests
  • Free cash flow burn -$37.2M, improved from -$45.8M YoY
  • Cash and equivalents $1.1B as of Sep 30, 2026

Financial Impact

Revenue beat consensus by $10.4M (+3.0%); EPS missed by $0.62; guidance raised by $20M at midpoint

revenueepsguidancegross marginfree cash flow

Segment Breakdown

SegmentRevenueGrowth
Oncology$231.3M+25.4%
Biopharma and data$59.0M+7.7%
Screening$67.6M+180.4%
Licensing and other$3.1M+60.2%

Risk Factors

  • GAAP net loss widened to -$124.4M from -$92.7M YoY due to rising operating expenses
  • Full-year free cash flow burn guidance widened to $205M-$220M from $195M-$205M
  • Non-GAAP operating expenses raised to $1.105-$1.125B, indicating continued investment spend

Market Snapshot

Exchange
Nasdaq
Sector
Services-Medical Laboratories
Analyst Consensus
92% bullish (36 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001576280-26-000043
Document: gh-20261105.htm0001576280-26-000043
Document: 0001576280-26-000043-index-headers.html0001576280-26-000043
Document: 0001576280-26-000043-index.html0001576280-26-000043
Document: 0001576280-26-000043.txt0001576280-26-000043
8-K Data (Synthetic)0001576280-26-000043

Track record

38 reports on GH

Performance horizon

3 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +22.49% at T+60 after the May 27, 2026 report. 3 of 6 went positive at some point.

Filters
  1. Nov 16, 2026today 144 Neutral 2/10 Entry $145.04 Now $144.03 −0.70% settles Dec 16
  2. Nov 12, 20264d ago 3 Neutral 1/10 Entry $151.70 Now $144.03 −5.06% settles Dec 14
  3. Nov 12, 20264d ago 3 Neutral 2/10 Entry $151.70 Now $144.03 −5.06% settles Dec 14
  4. Nov 5, 202611d ago 8-K Bullish 6/10 Viewing Entry $150.87 Now $144.03 −4.53% settles Dec 7
  5. Nov 5, 202611d ago SC 13G Neutral 3/10 Entry $153.43 Now $144.03 −6.13% settles Dec 4
  6. Nov 3, 202613d ago 8-K Neutral 2/10 Entry $168.58 Now $144.03 −14.56% settles Dec 3
  7. Nov 3, 202613d ago 8-K Neutral 2/10 Entry $175.00 Now $144.03 −17.70% settles Dec 2
  8. Oct 21, 202626d ago Institutional Cluster Neutral 3/10 Entry $162.94 Now $144.03 −11.61% settles Nov 19
  9. Oct 14, 20264w ago 144 Neutral 2/10 Entry $165.88 to $154.86 Now $144.03 −13.17% ▼ −6.64% −4.74% vs SPY
  10. Sep 17, 20268w ago Insider Cluster Bearish 5/10 Entry $179.38 to $158.60 Now $144.03 +19.71% ▲ +11.58% +11.79% vs SPY
Showing 10 of 38

US Market Status

Market Closed · Opens in 7h 12m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026